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Nephrolithiasis remains a formidable health problem in the
United States and worldwide. A very important but
underaddressed area in nephrolithiasis is the accompanying
bone disease. Epidemiologic studies have shown that
osteoporotic fractures occur more frequently in patients with
nephrolithiasis than in the general population. Decreased
bone mineral density and defects in bone remodeling are
commonly encountered in patients with calcium
nephrolithiasis. The pathophysiologic connection of bone
defects to kidney stones is unknown. Hypercalciuria and
hypocitraturia are two important risk factors for stone
disease, and treatments with thiazide diuretics and alkali,
respectively, have been shown to be useful in preventing
stone recurrence in small prospective trials. However, no
studies have examined the efficacy of these agents or other
therapies in preventing continued bone loss in calcium stone
formers. This manuscript reviews the epidemiology,
pathophysiology, and potential treatments of bone disease
in patients with nephrolithiasis.
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Nephrolithiasis is a common condition with a lifetime risk
exceeding 6.3% in men and 4.1% in women in the United
States.1 The prevalence of nephrolithiasis has increased in
both genders and among all ethnic groups within the last
quarter of the 20th century.1 Kidney stone disease imposes a
high health and economic burden on our society.2 Nephro-
lithiasis has been recognized as a potential risk factor for
osteoporotic fractures.3,4 Despite the association between
nephrolithiasis and bone fractures and the attendant high
morbidity and health costs of both conditions, patients
with nephrolithiasis are neither commonly evaluated for nor
subsequently treated for bone loss. The consequences are
twofold: (1) bone mineral density (BMD) analyses should be
included in the routine evaluation of stone formers and (2)
low BMD should be treated if present. The question of how
to best treat these patients has unfortunately not yet been
answered. Thus, studies evaluating the pathophysiology and
effects of commonly used therapies for nephrolithiasis on
bone health are much required.
EPIDEMIOLOGY
In a population-based cohort study, the number of patients
with symptomatic kidney stone disease experiencing their
first vertebral fracture during a mean follow-up of 19 years
was fourfold higher than in the general non-stone-forming
population3 (Figure 1). Fractures reported in this study
affected the cancellous bone more severely the than cortical
bone. Axial skeletal fractures affected both genders and
increased with age.3 Fracture risk increased with time,
reaching a cumulative incidence of 45% for women and
28% for men at 30 years. Another epidemiological study that
comprised 14,000 men and women (NHANES (The National
Health and Nutrition Examination Survey) III) also estab-
lished an association between history of kidney stone, low
BMD, and a higher prevalence of fractures.4 This association
was present in both genders but was stronger in males than in
females. Thus, fractures among stone formers have been
far more prevalent than those among non-stone formers and
are a significant cause of morbidity in these patients.
Therefore, given the growing number of stone formers, the
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establishment of effective preventive measures represents an
important public health issue.
POTENTIAL PATHOPHYSIOLOGICAL MECHANISMS
CONTRIBUTING TO OSTEOPOROSIS IN STONE FORMERS
Calcium nephrolithiasis is a multisystem disease5 with bone
mineral loss and fractures as one of the known complica-
tions.3,4 Osteoporosis is a complex heterogeneous disorder
characterized by abnormal bone remodeling, which culmi-
nates in reduced BMD, deterioration of microarchitectural
integrity of the bone, and increased risk of fracture.6 Even
taking into account the heterogeneity of definitions and
methods of determining BMD, reduced BMD is a homog-
enous finding in calcium stone-forming patients as
described in many studies7–26 (Table 1). An analysis of all
previously conducted studies revealed that bone mineral loss
does not spare any skeletal site, with 40% of total patients
showing diminished BMD at the vertebral spine, 31% at the
proximal hip, and 65% at the radius (Table 2). These
numbers are in line with the findings of the large cohort
studies mentioned.3,4 One drawback of the previous studies is
that some were performed before the definition of osteo-
porosis and application of T-score by the World Health
Organization. Low BMD was present in both hypercalciuric
and normocalciuric kidney stone-forming subjects.9,12,16
Although a greater reduction in BMD is observed in those
with hypercalciuria,9,12,16,21,27 low BMD is not a unanimous
finding in normocalciuric kidney stone formers.15,18,21,23
Therefore, as BMD is a known surrogate marker of bone
strength, it is logical to suggest that hypercalciuric stone-
forming subjects will carry the highest risk of bone disease.
Static and dynamic bone histomorphometric studies have
consistently illustrated diminished bone formation in this
population23,28–34 (Table 3). However, the exact pathophy-
siological mechanism(s) of bone loss in stone formers
remains unknown. Dietary components, genetic factors,
hormonal influences, and local cytokines all seem to be
associated with altered bone formation in patients with
nephrolithiasis.
The major focus has been on the association between
idiopathic hypercalciuric stone formers and bone disease.
There has been no study using bone histomorphometry and
dual-energy x-ray absorptiometry to link bone disease to
patients with distal renal tubular acidosis and kidney stones.
However, in a short-term metabolic study, negative calcium
balance was corrected with potassium alkali treatment in
patients with incomplete distal renal tubular acidosis.35 In
one study, in both male and female patients with osteo-
porosis, the prevalence of incomplete distal renal tubular
acidosis was reported to be as high as 44% in men and 20%
in premenopausal women.36 Similarly, the prevalence of
incomplete and complete distal renal tubular acidosis is
frequent in patients with medullary sponge kidney at
33–40%.37,38 Very recently, it has been demonstrated that
59 and 12% of patients with medullary sponge kidney have
baseline BMD in the osteopenic and osteoporotic range,
respectively.39 More importantly, treatment with potassium
citrate for at least 12 months improved BMD, specifically at
the vertebral spine. These changes and those at the total hip
were significantly correlated with a decrease in urinary
calcium and an increase in urinary citrate excretion,
indicative of the positive effect of alkali treatment on bone.39
Environmental factors
Both high salt and high protein consumption contribute
to the increased prevalence of kidney stone40 and bone
disease.15,16 High salt and protein consumption increase
urinary calcium excretion through various mechanisms,
including decreased renal tubular calcium reabsorption,
hyperfiltration, provision of an acid load, decreased urine
pH, and increased urinary prostaglandin excretion.41–45 One
shared pathophysiological mechanism between protein and
salt-induced hypercalciuria is the development of a subtle
metabolic acidosis,45 which is known to inhibit osteoblastic
matrix protein synthesis and alkaline phosphatase activity
while stimulating prostaglandin E2 production.
46–48 The
increased osteoblastic prostaglandin E2 production increases
osteoblastic expression of receptor activator for nuclear
factor kB ligand (RANKL), a major downstream cytokine
that stimulates osteoclastogenesis, by binding to its recep-
tor RANK.49 In vitro studies have shown that low ambient
bicarbonate concentration decreases the expression of
osteoblastic extracellular matrix protein, including type I
collagen,46,48 osteopontin, matrix gla protein,47,50 and increases
the expression of cyclooxygenase-2 (ref. 51) and RANKL.49,52
Genetic factors
Some studies have suggested a genetic role in the pathogen-
esis of bone loss among stone formers. Mutations or
polymorphisms in the soluble adenylyl cyclase gene
(ADCY10) genes have been linked to vertebral bone loss in
kidney stone patients with absorptive hypercalciuria.53,54
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Figure 1 |Cumulative incidence of vertebral fracture among
Rochester, Minnesota, residents following an initial episode
of symptomatic nephrolithiasis. The solid line indicates
observed. The dashed line indicates expected. Figure reprinted
with permission by Melton et al.3
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Table 1 | Changes in BMD in calcium kidney stone formers
Number of subjects BMD site
Author Study subjects Male Female Controls Spine Hip Radius Measurement technique
Alhava et al.7 Single or recurrent urolithiasis 54 21 21 k Americum-241 g-ray
attenuation
Lawoyin
et al.8
Absorptive hypercalciuria 94 23 Not reported 2 Single-photon absorptiometry
Renal hypercalciuria 28 16 k
Primary hyperparathyroidism 22 31 k
Osteoporosis 14 55 k
Fuss et al.9 Absorptive hypercalciuria 24 19 Not reported k Single-photon absorptiometry
Renal or resorptive
hypercalciuria
7 18 k
Normocalciuric 35 6 k
Barkin et al.10 Idiopathic hypercalciuria 86 23 84 k Calcium-binding
index
Neutron-activation analysis
Fuss et al.11 Free diet 63 0 16 2 Single-photon absorptiometry
Low calcium diet 60 0 k
Pacifici et al.12 Absorptive hypercalciuria 29 18 28 (24 males
and 4 females)
k Quantitative computerized
tomographyFasting hypercalciuria 16 7 k
Bataille et al.13 Dietary hypercalciuria 12 6 61 (41 males
and 20 females)
2 Quantitative computerized
tomographyDietary independent
hypercalciuria
17 7 k
Borghi et al.14 Dietary hypercalciuria 13 7 0 2 Dual-photon absorptiometry
Dietary independent
hypercalciuria
14 7 k
Pietschmann
et al.15
Absorptive hypercalciuria 42 20 0 k Dual-energy X-ray
absorptiometry,
dual-photon
absorptiometry, and
single-photon absorptiometry
Fasting hypercalciuria 24 3 k
Normocalciuric 25 6 2
Jaeger et al.16 Hypercalciuric 49 0 234 k k Dual-energy X-ray
absorptiometryNormocalciuric 61 0 k k
Zanchetta
et al.17
Fasting hypercalciuria 15 23 50 (20 males
and 30 females)
k Dual-photon absorptiometry
Absorptive hypercalciuria 5 7 k
(females)
2
(males)
Weisinger
et al.18
Hypercalciuric 4 13 12 (4 males
and 8 females)
k Dual-energy X-ray
absorptiometry
Normocalciuric 4 8 2
Ghazali et al.19 Idiopathic hypercalciuria 15 1 10 (8 males
and 2 females)
k Quantitative computerized
tomographyDietary hypercalciuria 9 1 2
Giannini
et al.20
Fasting hypercalciuria 8 23 13 (10 males
and 3 females)
k k Dual-energy X-ray
absorptiometry
Absorptive hypercalciuria 13 5 k 2
Trinchieri
et al.21
Hypercalciuria 10 0 2 2 Dual-energy X-ray
absorptiometry
Normocalciuria 34 2 2
Tasca et al.22 Fasting hypercalciuria 27 12 15 k Dual-energy X-ray
absorptiometryAbsorptive hypercalciuria 20 11 Not reported
Misael da
Silva et al.23
Idiopathic hypercalciuria 11 11 10 (5 males
and 5 females)
k k Dual-energy X-ray
absorptiometry
Normocalciuric 8 10 2 2
Asplin et al.24 Stone formers 15 7 37 (14 males
and 23 females)
k k Dual-energy X-ray
absorptiometry
Vezzoli et al.25 Hypercalciuria 29 35 0 k k Dual-energy X-ray
absorptiometryNormocalciuria 15 27 k k
Caudarella
et al.26
Stone formers (27% with
hypercalciuria)
102 94 196 (102 males
and 94 females)
k Dual-energy X-ray
absorptiometry,
quantitative ultrasonography
Abbreviation: BMD, bone mineral density.
k Indicates decreased BMD.
2 Indicates no change in BMD.
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A modest association was later found between ADCY10
polymorphism and vertebral BMD in premenopausal
Caucasian women.55 Although soluble adenylyl cyclase has
been shown to mediate the regulation of osteoclast function
by ambient bicarbonate concentration,56 the mechanism of
how it can lead to osteoporosis is unknown. Another study
conducted in a large population from Iceland and the
Netherlands associated sequence variants in the CLDN14
gene (which encodes for tight junction claudin-14) with
kidney stones and reduced BMD at the hip.57 Similarly, it is
unclear how a paracellular protein affects bone remodeling or
bone cell function.
In addition, some genetically heterogeneous disorders
that are manifested in childhood or early adulthood
and are associated with hypercalciuria, nephrocalcinosis,
nephrolithiasis, and rachitic bone disease include Dent’s
disease (mutations in the chloride/proton exchange trans-
porter (CLC-5)) and Lowe’s syndrome (mutations in phos-
phatidylinositol-4,5-biphosphate-5-phosphatase (OCRL1)).58–60
The role of these genes in the bone disease seen in the general
stone-forming population is unclear. Although a mutation in
the gene encoding phosphate transporter NaPi2a was initially
linked to nephrolithiasis and defective bone mineralization,61
further studies do not support this association.62,63
Hormones and local cytokines
Abnormal bone remodeling is an important feature in
hypercalciuric stone formers.23,28,29,31,32,34,64 Whereas bone
histomorphometric studies have displayed some inconsistencies
with respect to bone resorption, many studies have unanimously
demonstrated defective bone formation 28,29,31,32,34,65 (Table 3).
The mechanisms responsible for impaired bone formation in
hypercalciuric stone formers include elevated serum 1,25-
dihydroxyvitamin D (1,25(OH)2D) levels, which occur in
40–60% of hypercalciuric stone formers, whereas the
remaining patients have normal serum levels.66–69 Moreover,
peripheral blood monocyte vitamin D receptor levels in all of
these subjects were high.70 Target organ action of normal
circulating 1,25(OH)2D in the bone, kidney, and intestine
may be amplified by high vitamin D receptor activity. At high
doses, 1,25(OH)2D increases bone resorption and decreases
bone collagen synthesis.71 Low levels of transforming growth
Table 2 | Prevalence of low BMD at various skeletal sites in
kidney stone formers (cumulative data from Table 1)
Prevalence
Skeletal sites
Total number
of patients
Number of patients
with low BMD
Percentage
(%)
Vertebral spine 975 388 40
Hip 450 141 31
Radius 627 410 65
Abbreviation: BMD, bone mineral density.
Table 3 | Bone histomorphometric characteristics in kidney stone formers
Author Study subjects Number of subjects Bone histomorphometric profiles
Bordier et al.28 Dietary hypercalciuria 20 None
Renal hypercalciuria 19 Increased osteoclast and osteoblast surfaces
Hypophosphatemia 21 Increased osteoclastic and eroded surfaces (within normal range),
decreased osteoblast surfaces, decreased osteoid parameters
Controls 12
Malluche et al.29 Absorptive
hypercalciuria
15 Low-normal osteoclastic bone resorption, low osteoblastic activity,
decreased fraction of mineralizing osteoid seams, decreased mineralization
apposition rate
Controls 22
de Vernejoul et al.30 Idiopathic
hypercalciuria
30 (20 males
and 10 females)
Decreased trabecular volume, decreased active osteoblastic surface,
decreased active bone resorption surface
Controls 187
Steiniche et al.31 Idiopathic
hypercalciuria
33 (22 males
and 11 females)
Increased bone resorption surfaces (decreased refilling of lacunae with low
bone formation), decreased bone formation rate, increased mineralization
lag times
Controls 30 (19 males
and 11 females)
Heilberg et al.32 Fasting
hypercalciuria
6 Males Increased eroded surface, decreased osteoid surface, decreased bone
formation rate with a complete lack of tetracycline double labeling
Controls No information
Bataille et al.33 Idiopathic
hypercalciuria
24 (20 males
and 4 females)
Low eroded surface, low bone volume, low osteoid surface, thickness,
mineral apposition rate, adjusted apposition rate, and bone formation rate
Controls 18 (9 males
and 9 females)
Misael da Silva et al.23 Idiopathic
hypercalciuria
22 High eroded surface, increased osteoblastic bone surface, no change in
trabecular thickness
Controls 94
Heller et al.34 Absorptive
hypercalciuria
9 (6 males
and 3 females)
Relatively high bone resorption (osteoclast surface/bone surface—mean
value within the normal limit), lower indices of bone formation (osteoblast
surface/bone surface), decreased wall thickness
Controls 9 (6 males
and 3 females)
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factor-b, a growth factor that stimulates bone formation and
bone mineralization,71,72 were found in bone immunostains
of hypercalciuric stone formers.73 Transforming growth
factor-b expression was low in areas adjacent to osteoid
surfaces73 in patients with nephrolithiasis. Transforming
growth factor-b expression positively correlated with bone-
formation indices including osteoid volume, osteoblastic
surface, trabecular number, and mineralization surface, and
negatively correlated with bone resorption parameters, such
as trabecular separation. The increased bone resorptive
activity in idiopathic hypercalciuric stone formers was
initially attributed to increased production of bone resorptive
lymphokines.12,18,19 Regulation of bone remodeling has been
shown to be mediated by an interaction between receptor
activator of nuclear factor kB (RANK), receptor activator
of nuclear factor kB ligand (RANKL), and OPG (osteo-
protegerin) system in many disease states.74,75 A recent
study in undecalcified bone specimens from 36 transiliac
bone biopsies in idiopathic hypercalciuric patients displayed
an elevated bone expression of RANKL.73 It is likely that
cytokines and the RANK–RANKL–OPG system act synergis-
tically to stimulate bone resorption, whereas diminished
transforming growth factor-b or high 1,25(OH)2D impair
osteoblastic bone formation in hypercalciuric stone formers.
POTENTIAL THERAPEUTIC REGIMENS
Thiazide, thiazide analogs,76–87 and/or potassium alkali
treatment88–97 have been shown to avert recurrent kidney
stone formation in heterogeneous patient cohorts with
calcium oxalate nephrolithiasis (Figure 2). One ponders
whether such regimens are also efficacious for bone disease.
Therapeutic effect of alkali on the bone
Potassium citrate (K-Cit) is a drug widely used for the
prevention of recurrent calcium nephrolithiasis, which may
also prevent bone loss. Numerous studies have shown that
the administration of alkali reduces the bone-resorbing effect
of excess acid in healthy men and women without
nephrolithiasis.98–105 One randomized, double-blind, placebo-
controlled, prospective trial conducted in 161 postmenopau-
sal women with osteopenia, in which subjects were treated
with 30mequiv. K-Cit or 30mequiv. K-Cl for 1 year, reported
that K-Cit treatment significantly increased BMD at the
vertebral spine, femoral neck, and total hip.106 The increase
in BMD with K-Cit treatment was associated with an increase
in urinary citrate and decline in urinary net acid excretion,
indicative of sustained systemic alkalinization. In addition,
urinary deoxypyridinoline declined significantly with K-Cit
treatment.106 In contrast, another randomized, double-blind,
placebo-controlled, prospective 2-year trial in 276 healthy
postmenopausal women comparing K-Cit, 55 or 18.5me-
quiv./day, and placebo determined that K-Cit supplementa-
tion at both dosages did not increase BMD or decrease bone
turnover marker.107 In patients with nephrolithiasis, several
uncontrolled studies in diverse patient populations have
also shown improvement in BMD or a positive calcium
balance by K-Cit.35,39,108,109 In one open trial conducted in
16 men and 5 women with recurrent calcium nephrolithiasis,
treatment with K-Cit ranging between 20 and 60mequiv./day
for a mean duration of 44 months significantly increased
vertebral BMD by 3.1%, with a mean change in Z-score of
3.8% (Po0.001).108 Another study in 109 patients with
idiopathic calcium stone disease, 51 males and 58 females,
Bisphosphonate
ECF Ca2+ 
Filtration 
Reabsorption
Bone resorption 
Bone formation 
Thiazide 
Alkali 
–
+ +
+
+
–
Figure 2 |Mechanisms of action of potential therapeutic agents. ECF, extracellular fluid; ¼ inhibitory role; ¼ stimulatory role.
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showed treatment with K-Cit, 37mequiv./day for 2 years,
improved distal radial BMD by 1.75% (T-score: 1.43±1.02
vs 0.90±1.04, P¼ 0.0001).109
Mechanism(s) of action of alkali treatment on bone metabolism
The mechanisms by which alkali therapy inibits bone
resorption and improves bone mass include the induction
of hypocalciuria110 and a sustained stimulation of osteoblast
activity illustrated by increases in bone-formation markers
and a steady increase in BMD.99,106,111,112 Although histo-
morphometric studies in humans with alkali treatment are
not available, studies in rats have shown that a high acid load
increases bone resorption parameters, such as eroded surface
and osteoclastic surfaces.113 Furthermore, animals on a high
protein diet given K-Cit demonstrated significantly lower
static and dynamic evidence of bone resorption than did
animals on the same diet treated with K-Cl without signifi-
cant differences in bone-formation parameters.114 Thus,
potassium alkali treatment attenuates the skeletal effect of
substantial acid load provided by a high protein diet.
Effect of thiazide on the bone
Several epidemiological and randomized trials have demon-
strated that thiazide treatment significantly diminishes the
risk of hip fracture in premenopausal women, postmeno-
pausal women, and elderly men.115–133 In one study
conducted in a small number of osteoporotic men with
hypercalciuria, hydrochlorothiazide (HCTZ) treatment was
shown to annually increase BMD at the vertebral spine and
proximal hip by 8 and 3%, respectively.134 It has been
suggested that the hypocalciuric effect of thiazides and the
consequent decrease in serum parathyroid hormone (PTH)
levels may reduce bone turnover in postmenopausal
osteoporotic women with renal leak hypercalciuria.135
However, the increase in BMD with thiazide therapy was
sustained in a 2-year extension trial of a previous rando-
mized, placebo-controlled trial of HCTZ in 122 postmeno-
pausal women.132 From this study, one may conclude that the
thiazide effect on the bone is not solely mediated by lower
bone turnover (with reduced bone resorption and bone
formation).
Two open label studies have shown a protective effect of
thiazide treatment on bone mass in hypercalciuric nephro-
lithiasis.136,137 In one study, 24 patients were divided
randomly into two groups, and were treated for 1 year with
thiazides (chlorthalidone, 50mg/day) and potassium supple-
mentation or received no treatment. Those treated with
thiazide exhibited a significant increase in BMD of 3% in
total body, 2.5% in the arms, and 3.7% in the trunk
(Po0.001).137 However, these studies suffered from the use
of a historical control. The only histomorphometric bone
analysis performed in idiopathic hypercalciuric kidney stone
patients, both before and after thiazide treatment, supports
this result by showing a reduction in bone resorption.138 The
effect of HCTZ on decreasing urinary calcium excretion
and/or PTH concentrations is not persistent.132,133,139
In one study of postmenopausal women, HCTZ was
coadministered with exogenous 1,25(OH)2D (modeled to
mimic idiopathic hypercalciuric patients with enhanced
intestinal calcium absorption). During the 4-week treatment
with calcitriol (0.5mcg/day), there was a significant increase
in serum 1,25(OH)2D concentrations, intestinal calcium
absorption, and urinary calcium excretion (Po0.008). When
HCTZ was added, urinary calcium significantly declined, but
serum 1,25(OH)2D and intestinal calcium absorption
remained elevated. Thus, the estimated calcium balance
remained positive. These results were similar to those
obtained from patients with idiopathic hypercalciuria on
thiazide treatment.140 As a result, BMD at the lumbar spine
and proximal femur remained stable over 11–29 months of
treatment. Although this study was open ended and was
conducted in a small number of patients, it is suggestive of
the characteristic antiresorptive effect of agents, such as
thiazide and 1,25(OH)2D.
A unique presentation of osteoporosis associated with renal
hypercalciuria and secondary PTH stimulation is encountered
in a small fraction of postmenopausal osteoporotic women.
Eight individuals with fasting hypercalciuria (0.17±0.04mg/
100ml glomerular filtration) have been studied in the setting of
normocalcemia and slight PTH stimulation.135 This phenotype
is similar to patients with idiopathic hypercalciuria. In this
population, treatment with HCTZ (50mg/day for 12 months)
produced a significant decline in fasting hypercalciuria,
serum PTH, and urinary cAMP excretion. Histomorphometric
bone analysis showed reduced trabecular bone volume
without mineralization defect, consistent with the diagnosis
of osteoporosis. In four out of eight patients with high or
high-normal fractional resorption surfaces, reflective of PTH-
dependent osteoclastic bone resorption, treatment with thiazide
corrected secondary hyperparathyroidism and reduced frac-
tional resorption surfaces.
Mechanism(s) of action of thiazide on bone metabolism
The effect of thiazides on the bone may extend beyond
its anticalciuric actions. Similar to alkali treatment, thiazide
diuretics may potentially stimulate osteoblastic bone
formation. In vitro, thiazides have a selective effect on human
osteoblast-like cell lines, directly stimulating osteocalcin
production in human osteoblasts and increasing the expres-
sion of thiazide-sensitive sodium chloride cotransporter
in osteoblast-like cells, which is the target of thiazide
diuretics.141–143 The mitogenic action of thiazide and the
thiazide-related diuretic, indapamide, has been shown to
be in part due to increased osteoblastic cell prolifera-
tion.144,145 This in vitro effect was also associated with
inhibition of osteoclastic bone resorption as a result of the
reduction of osteoclastic cell differentiation mediated
through direct inhibition of hematopoietic precur-
sors.144,146,147 Therefore, the overall effect of thiazide
diuretics and alkali treatment may be sustained stimulation
of osteoblastic bone formation in combination with inhibi-
tion of osteoclastic bone resorption.
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Combined dietary and pharmacological treatment on BMD
in absorptive hypercalciuric patients
In a prospective study in 28 patients with hypercalciuria,
combined treatment with thiazide or indapamide and K-Cit
over a mean duration of 7 years increased BMD at the L2–L4
spine by 7.1% and at the femoral neck by 4.1% compared
with normal age- and gender-matched patients (Z-score)
(Po0.001) (Figure 3). This combined treatment also
increased the normal peak values (T-score) by 5.7 and
4.6%, respectively (Po0.001).136 During treatment, urinary
calcium decreased (346±85mg/day to 248±79mg/day,
Po0.001), whereas urinary pH and citrate increased
(6.02±0.39 to 6.41±0.46 (Po0.01) and 576±272mg/day
to 706±368mg/day (Po0.05), respectively). Consequently,
urinary saturation of calcium oxalate decreased by 46%
and stone formation decreased from 2.94 to 0.05 per year
(Po0.001).136
OTHER THERAPEUTIC OPTIONS
Antiresorptive agents
Bisphosphonates are popular and effective antiresorptive
treatment drugs of osteoporosis. In genetic hypercalciuric
stone-forming rats, treatment with alendronate decreased
urinary calcium to that of the control littermate and created
a positive calcium balance.148 In two clinical studies in
hypercalciuric kidney stone formers, treatment with alen-
dronate also showed lower urinary calcium excretion.34,149
In the only study in idiopathic hypercalciuric patients,
treatment with alendronate for 1 year showed an increase in
trabecular BMD.18 As existing histomorphometric data
suggest that hypercalciuric kidney stone formers may exhibit
decreased bone formation, bisphosphonates may not be the
most rational and effective treatment in this population
because of the very nature of bisphosphonates suppressing
bone turnover. This notion is underlined by recent reports on
the occurrence of ‘atypical’ subtrocanteric and diaphyseal
fractures of the femoral shaft with long-term bisphosphonate
use for postmenopausal osteoporosis.150 However, these
atypical fractures have not been described with bispho-
sphonate use in kidney stone formers.
Anabolic agents
The only bone-stimulating agent available in the United States
that has been approved for the treatment of postmenopausal
osteoporotic patients is teriparatide, a PTH analogon with a
treatment duration restricted to 2 years.151 With regard to its
application in stone formers, there are concerns about its
potential hypercalciuric effects, which might aggravate stone-
formation activity in predisposed subjects. Although the
reported degree of hypercalciuria with teriparatide was mild
in elderly osteoporotic subjects,151,152 one may still have
reservations when using this agent in younger hypercalciuric
kidney stone-forming populations.
Calcium and vitamin D supplementation
There has been no consensus over the treatment of
hypercalciuric kidney stone formers with calcium and vitamin
D supplementation. Some studies have shown an association
between vitamin D intake and calcium intake with kidney
stones, but others have not.153,154 Moreover, the relationship
between serum 25-hydroxyvitamin D and the risk of kidney
stone formation is controversial.155,156 Owing to these
discrepancies, clinicians typically recommend abstinence from
calcium and vitamin D supplementation in the stone-forming
population. On the basis of these circumstances, further studies
are required to determine the risk of calcium and vitamin D
treatment in patients with hypercalciuric nephrolithiasis.
CONCLUSIONS
As noted above, fractures are significantly more common
among patients with nephrolithiasis. The attendant morbid-
ity, and occasional mortality, is greatly underappreciated and
patients with nephrolithiasis represent an important popula-
tion of patients at increased risk for osteoporosis and
fractures. This increased fracture risk may be evident in both
hypercalciuric and normocalciuric kidney stone-forming
subjects as low BMD is present in each population. Owing
to these circumstances, it is logical to propose that BMD
measurement should be considered in all kidney stone-
forming subjects. However, because of insurance constraints
imposed in the United States, this procedure is not
reimbursable for these subjects at this time. Similarly, the
use of non-invasive bone turnover markers has been
challenged even for the diagnosis and treatment of post-
menopausal women by most insurance agencies and
Medicare in the United States. Although the authors feel
that the utility of these markers is important in this
population for the determination of a specific therapeutic
agent and also for the assessment of response to such
treatment, this cannot be recommended in clinical practice at
this time because of the aforementioned constraints.
Pre Post Pre Post Pre Post 
L2-L4 
%
 o
f n
or
m
al
 a
ge
- a
nd
 g
en
de
r-
m
a
tc
he
d 
va
lu
es
50
60
70
80
90
100
110
120
†
Radial
shaft 
**
Femoral
neck 
†
Figure 3 | The effect of thiazide/indapamide and K-Cit on
BMD of the L2–L4 spine, femoral neck, and radial shaft of
hypercalciuric kidney stone formers. Data are expressed as
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Therefore, such patients are not commonly evaluated for
or subsequently treated for bone loss. Thus, studies
evaluating the pathophysiology of bone involvement in stone
formers and effects of commonly used therapies for
nephrolithiasis on bone health are very much required. On
the basis of currently available data, a therapeutic regimen
that stimulates bone formation is potentially the ideal
approach as it differs from bisphosphonates, which are
known to decrease bone turnover. One approach may be the
utilization of combined HCTZþK-Cit because of its
sustained effect on bone formation.
In addition, citrate plus thiazide as initial therapy in
patients with nephrolithiasis can potentially diminish the
burden of stone formation, as well as significantly reduce
bone loss and fracture, resulting in an enormous improve-
ment in patient health and a significant reduction in
health-care expenditures. At present, patients with calcium
nephrolithiasis are not uniformly treated with thiazides,
citrate, or a combination thereof as therapy for stone disease.
In many large stone clinics, treatment in both normocalciuric
and hypercalciuric stone formers initially consists only of
dietary modifications (a reduction in sodium, oxalate, and
purine precursor intake) and an increase in fluid intake. If
subsequent evaluation fails to demonstrate a reduction in
stone metabolic activity or hypercalciuria, patients are placed
on therapy with either potassium citrate or a thiazide. If
future trials demonstrate an increase in bone mass and a
reduction in stone metabolic activity following the institu-
tion of therapy with thiazide, alkali, or a combination,
conservative dietary therapy for treatment of stone disease
may be inadequate for bone health. To date, the efficacy of
various treatment modalities in reducing bone fracture and
decreasing kidney stone burden has not been explored in a
randomized, placebo-controlled trial. Ultimately, the impact
of such treatment in the care of patients with nephrolithiasis
will be immense.
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